Skip to main content
SpringerLink
Log in

Adalimumab/infliximab

Demyelinating disease: 4 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Lee HJ, et al. Demyelination amongst patients exposed to tumour necrosis factor-alpha inhibitor (TNFi): A case series. International Journal of Rheumatic Diseases 22 (Suppl. 3): 121 (plus poster) abstr. 3-067, Apr 2019. Available from: URL: http://doi.org/10.1111/1756-185X.13545 [abstract] - Australia

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/infliximab. Reactions Weekly 1752, 17 (2019). https://doi.org/10.1007/s40278-019-61520-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-61520-1

Search

Navigation